Advanced Renal Technologies Inc. WA. USA (ART) has developed a new dialysate formulation that addresses patients needs and brings treatment to a more effective level. Containing Citric Acid as the acidifying agent, it is the first major change in dialysate formulation in over 30 years, breaking away from traditional formulations that contain acetic acid. It is cleared for use by the FDA for all patients, is already on the market and is in use in many clinics around the world.
Advanced Renal Technologies, Inc. provides an advanced dialysis fluid concentrate (dialysate) formulation containing citric acid. DRY Citrasate is DRYalysate® , a dry powdered version that can be mixed by the user to make A concentrate. The use of citric acid in the dialysate offers a safe and effective way to provide dialysis therapy. Citrate dialysis provides improved treatment for patients on routine long-term hemodialysis. Citrate dialysate is safe and effective in all dialysis patients. DRY Citrasate is available in all standard formulations.
Shifa Remedies is the sole and exclusive licensee of DRY Citrasate® (Patented) (DRYalysate®) product in India, Bangladesh, Srilanka, Nepal, Bhutan, and Pakistan under license from Advanced Renal Technologies Inc., (ART) Washington, U.S.A.